The Only Monthly Membership With a Positive ROI!
España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Only Monthly Membership With a Positive ROI!
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Antibe Therapeutics
ATBPF
OTCEM
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.378000
0.16
75.32%
After Hours: Mar 5, 8:00 AM EDT
15 minutes delayed
Get Report
Comment
Antibe Therapeutics (ATBPF) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Antibe Therapeutics (OTC:ATBPF) Stock
Antibe Therapeutics Stock (OTC: ATBPF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, September 12, 2022
ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul…
Zacks Small Cap Research
Friday, July 08, 2022
ATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…
Zacks Small Cap Research
Wednesday, February 16, 2022
ATE.TO: First Human PK/PD Studies Underway in Otenaproxesul's Post-Operative Pain Program…
Zacks Small Cap Research
Wednesday, December 01, 2021
ATE.TO: Development Plan in Place for Otenaproxesul in Acute Pain…
Zacks Small Cap Research
Monday, October 18, 2021
ATE.TO: Pivoting to Acute Pain Relief for Otenaproxesul…
Zacks Small Cap Research
Friday, August 27, 2021
ATE.TO: Awaiting Update on Otenaproxesul Following AME Study Pause
Zacks Small Cap Research
Wednesday, August 04, 2021
ATE.TO: Unexpected Liver Enzyme Elevations Leads to Pause in AME Trial…
Zacks Small Cap Research
Thursday, July 01, 2021
ATE.TO: Phase 3 Enabling Activities Ongoing; Phase 3 Adaptive Trial to Initiate 1Q22…
Zacks Small Cap Research
Tuesday, March 24, 2020
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
Monday, February 10, 2020
Stocks That Hit 52-Week Highs On Monday
Lisa Levin
Friday, January 31, 2020
Stocks That Hit 52-Week Highs On Friday
Lisa Levin
Wednesday, October 30, 2019
Stocks That Hit 52-Week Highs On Wednesday
Lisa Levin
Tuesday, October 29, 2019
Stocks That Hit 52-Week Highs On Tuesday
Lisa Levin
